Koninklijke Philips N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
28 jan 2009 - 10:38
Statutaire naam
Koninklijke Philips N.V.
Titel
Philips leads European 'SonoDrugs' project to develop image-guided localized drug delivery technologies
Bericht
January 28, 2009
PHILIPS LEADS EUROPEAN ‘SONODRUGS’ PROJECT TO DEVELOP IMAGE-GUIDED LOCALIZED DRUG DELIVERY TECHNOLOGIES
EUR 15.9 million project will seek to maximize therapeutic efficiency and minimize side effects of treatments for cancer and cardiovascular disease
Eindhoven, the Netherlands - Royal Philips Electronics today announced that it is leading a major new European project to develop drug delivery technologies that could significantly impact the treatment of cancer and cardiovascular disease. By allowing drugs to be delivered to disease sites via the patient’s bloodstream and then activated by focused ultrasound pulses, the SonoDrugs project aims to maximize the therapeutic efficiency and minimize the side effects of drug treatments for cancer and cardiovascular disease. The project, which involves a total of fifteen industrial partners, university medical centers and academic institutions from throughout the European Union (EU), will run for four years and has a budget of EUR 15.9 million, EUR 10.9 million of which is being funded under the EU’s 7th Framework program.
The SonoDrugs consortium consists of the industrial partners Philips (The Netherlands, Germany and Finland), Nanobiotix (France) and Lipoid (Germany); the university medical centers Erasmus Medical Center (The Netherlands) and Universitäts Klinikum Münster (Germany); and the academic institutions University of Cyprus (Cyprus), University of Gent (Belgium), University of Helsinki (Finland), University of London (United Kingdom), University of Tours (France), University Victor Segalen Bordeaux (France), University of Technology Eindhoven (The Netherlands) and the University of Udine (Italy).
Cardiovascular disease and cancer are currently the two biggest killers in the world. Although powerful drugs are available to treat certain types of cancer and cardiovascular disease they are mostly administered as intravenous or oral doses. This allows only very limited control over the distribu
Datum laatste update: 02 januari 2026